Accurate, consistent interpretation of the pathogenicity and associated risk for variants in cancer susceptibility genes is essential for effective management of patients and their families.  With clinical and laboratory representation from each of the 25 molecular diagnostic laboratories in the UK and ROI, we have established CanVIG-UK (Cancer Variant Interpretation Group UK).  Through our monthly meetings, we review challenging variants, have evolved systems for national sharing of variant data and have developed a consensus UK specification for interpretation of variants in cancer susceptibility genes.  We present CanVIG-UK as an exemplar ‘National Multidisciplinary Subspecialist Genomics Network’ by which we can deliver expert subspecialty best practice in genomic interpretation nationally. (By Dr. Alice Garrett, https://jmg.bmj.com/content/early/2020/03/13/jmedgenet-2019-106759 )